What is Cagrilintide?
Cagrilintide is a long-acting, once-weekly amylin analog developed by Novo Nordisk as part of a broader effort to build upon the success of GLP-1 receptor agonists with complementary mechanisms of action. Where semaglutide and tirzepatide work primarily through the incretin axis, cagrilintide operates through a completely different physiological pathway — the amylin system — which means combining the two can produce additive or even synergistic effects on weight loss and glycemic control that neither compound fully achieves alone.
Amylin is a 37-amino acid peptide co-secreted with insulin from the pancreatic beta cells in response to meals. It plays an underappreciated but genuinely important role in post-meal glucose regulation: it slows gastric emptying, suppresses post-prandial glucagon release, and communicates satiety signals to the brain through the area postrema in the brainstem. In people with type 2 diabetes and obesity, both amylin secretion and amylin receptor sensitivity are impaired, making the amylin system a meaningful and largely underexploited therapeutic target.
The first clinically available amylin analog, pramlintide (Symlin), demonstrated the concept but required multiple daily injections and had a relatively modest effect on body weight. Cagrilintide overcomes those limitations through a sophisticated structural engineering approach — fatty acid conjugation that enables tight albumin binding and dramatically extends the half-life to approximately one week, matching the dosing convenience of once-weekly semaglutide. This compatibility was not incidental; Novo Nordisk designed cagrilintide with the explicit goal of combining it with semaglutide in a single co-formulated injection.
That combination product, known as CagriSema, is currently being evaluated across the REDEFINE clinical trial program. Early-phase results have generated considerable scientific and commercial interest because the degree of weight loss observed — particularly in the REDEFINE 1 trial — substantially exceeds what has been achieved with semaglutide alone. Understanding why that happens requires a closer look at how cagrilintide actually works at the receptor and systems level, which is where the mechanistic picture becomes genuinely compelling.
For a broader comparison of GLP-1 and amylin-based compounds, the Peptide Database has detailed entries on semaglutide, tirzepatide, and related analogs. If you’re trying to understand dosing strategies for any of these compounds, the Peptide Calculator is a useful starting point.
Research Benefits
- Substantial weight reduction in combination with semaglutide: CagriSema has demonstrated mean weight loss of approximately 22–25% of body weight in phase 2 trials, significantly outperforming either agent alone at matched doses.
- Complementary mechanism to GLP-1 agonism: Because cagrilintide acts through the amylin receptor system rather than GLP-1 receptors, combining the two compounds engages redundant satiety pathways and metabolic brakes simultaneously.
- Meaningful HbA1c reduction: CagriSema has produced clinically significant reductions in glycated hemoglobin in participants with type 2 diabetes, potentially offering a dual-purpose obesity and diabetes therapy.
- Slowed gastric emptying via a distinct pathway: Cagrilintide delays gastric emptying through vagal neural mechanisms rather than the gastric motility pathway engaged by GLP-1 agonists, providing additive post-meal glucose control.
- Glucagon suppression independent of GLP-1: Cagrilintide suppresses post-prandial glucagon through the amylin system, adding a second layer of glucoregulatory control on top of GLP-1 mediated glucagon inhibition.
- Once-weekly dosing convenience: The long half-life achieved through fatty acid conjugation allows cagrilintide to be dosed weekly, matching semaglutide’s schedule and enabling the co-formulation strategy.
- Favorable tolerability profile in combination: Phase 2 data from CagriSema trials suggests the combination is generally well-tolerated, with gastrointestinal side effects that are broadly similar to semaglutide alone despite the additional amylin activity.
- Potential cardiovascular benefit: Amylin analogs have shown favorable effects on post-prandial lipemia and glycemic excursions, factors associated with cardiovascular risk, though longer-term cardiovascular outcomes data for cagrilintide specifically are still maturing.
- Preservation of lean mass relative to total weight lost: Early body composition analyses suggest that CagriSema may produce a favorable ratio of fat mass to lean mass loss, though this requires confirmation in larger trials.
How Cagrilintide Works
AMY1, AMY2, and AMY3 Receptor Binding
The amylin receptors — designated AMY1, AMY2, and AMY3 — are heterodimeric complexes formed by the combination of the calcitonin receptor (CTR) with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3, respectively). This unusual receptor architecture is worth understanding because it explains why amylin has a somewhat different pharmacological profile than single-subunit GPCRs and why selectivity between amylin receptor subtypes is difficult to engineer.
Cagrilintide, like native amylin and pramlintide, activates all three amylin receptor subtypes. The CTR component of the complex signals primarily through Gs-coupled pathways, elevating intracellular cAMP and activating PKA-dependent signaling cascades. The RAMP component modulates receptor trafficking, ligand binding kinetics, and downstream signaling bias in ways that are still being fully characterized. In terms of tissue distribution, AMY1 and AMY3 are particularly enriched in the area postrema and nucleus tractus solitarius of the brainstem — structures that lack a blood-brain barrier and therefore directly sense circulating amylin concentrations. This anatomical arrangement is why amylin acts as a genuine meal-termination signal rather than a slow-acting hormonal regulator.
Cagrilintide’s structural modifications — primarily the addition of a C18 fatty diacid chain via a linker at the lysine residue — increase albumin binding and reduce renal clearance without substantially altering receptor binding affinity at the AMY receptors. This is a technically non-trivial achievement: adding a large hydrophobic chain to a peptide that needs to activate a specific receptor complex while retaining potency requires careful iterative optimization of the linker chemistry and attachment point.
Area Postrema Satiety Signaling and Central Appetite Suppression
Perhaps the most important mechanism of cagrilintide from a weight loss standpoint is its action on the area postrema (AP) and the adjacent nucleus tractus solitarius (NTS). These brainstem structures constitute a critical hub in the body’s meal-monitoring circuitry. The AP sits outside the blood-brain barrier, positioned to detect hormonal signals in the systemic circulation and relay that information into the central nervous system.
When cagrilintide binds AMY1 and AMY3 receptors in the AP and NTS, it activates neurons that project into hypothalamic circuits controlling appetite and energy expenditure, particularly the arcuate nucleus. This engagement complements GLP-1 receptor signaling in several ways: GLP-1 receptors are also expressed in the NTS and AP but activate partially overlapping and partially distinct neuronal populations. The downstream convergence on melanocortin and AgRP/NPY circuits in the arcuate nucleus means that simultaneous activation of both pathways produces satiety signals through multiple parallel inputs — which may explain why CagriSema produces more weight loss than dose-matched semaglutide alone.
Critically, the area postrema pathway mediates a relatively rapid meal-termination signal. Amylin levels rise within minutes of meal initiation, acting as an early brake on eating behavior — different from the longer-latency vagal and hormonal signals that GLP-1 contributes. This temporal complementarity is not just mechanistically interesting; it may translate directly into more effective meal-size reduction across the full course of eating behavior.
Vagal Gastric Emptying Delay and Glucagon Suppression
Beyond central satiety signaling, cagrilintide exerts important peripheral effects that contribute to its overall metabolic profile. One of the best-documented amylin actions is slowing of gastric emptying through a vagally-mediated mechanism. Amylin receptors expressed on vagal afferents modulate the rate at which the stomach empties its contents into the duodenum, effectively controlling the pace of nutrient delivery to the small intestine. By slowing this process, cagrilintide attenuates the rate of post-meal glucose absorption, reducing the amplitude of post-prandial glucose excursions. This is mechanistically distinct from the gastric emptying effects of GLP-1 agonists, which operate through GLP-1 receptors on gastric smooth muscle and the enteric nervous system — different molecular targets, different neural pathways, and therefore potentially additive effects when both are active simultaneously.
Cagrilintide also suppresses post-prandial glucagon secretion from pancreatic alpha cells. This effect is mediated through amylin receptors on alpha cells or through paracrine signals from beta cells — the precise mechanism is still being clarified — but the functional outcome is a reduction in the glucagon spike that normally follows a meal. Since glucagon promotes hepatic glucose output (glycogenolysis and gluconeogenesis), suppressing this spike reduces post-meal hepatic glucose production. Combined with the gastric emptying effect on intestinal glucose absorption, cagrilintide addresses two distinct contributors to post-prandial hyperglycemia through mechanisms largely independent of GLP-1 receptor activation.
Research Findings
REDEFINE 1: CagriSema vs. Semaglutide in Obesity
The REDEFINE 1 trial is the most watched dataset in the CagriSema program. This phase 3 trial enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, and randomized participants to CagriSema (2.4 mg semaglutide plus 2.4 mg cagrilintide weekly) versus semaglutide 2.4 mg alone versus placebo. The primary endpoints were percentage change in body weight and the proportion of participants achieving ≥5% weight loss.
Results from the REDEFINE 1 trial showed that CagriSema produced a mean weight loss of approximately 22.7% at 68 weeks, compared to roughly 16.1% for semaglutide alone — a difference that represents a substantial improvement over the already-impressive benchmark set by semaglutide monotherapy. The proportion of participants achieving ≥20% weight loss was markedly higher in the CagriSema group, a threshold that begins to approach the weight loss typically achieved through bariatric surgery. These findings were considered highly significant because they demonstrated that the combination approach can push past the ceiling of what single-mechanism therapy can achieve, supporting the hypothesis that engaging complementary satiety and metabolic pathways produces genuine synergy rather than merely additive effects.
Notably, REDEFINE 1 also revealed that the tolerability profile of CagriSema was broadly manageable, with gastrointestinal adverse events being the most common class of side effect — consistent with the established profile of semaglutide — and serious adverse event rates that were not meaningfully elevated over semaglutide alone.
CagriSema in Type 2 Diabetes: Glycemic and Weight Effects
A separate arm of the REDEFINE program has evaluated CagriSema specifically in participants with type 2 diabetes, a population in whom both weight loss and glycemic control are clinical priorities. Amylin deficiency is a well-documented feature of type 2 diabetes — beta cell loss impairs both insulin and amylin co-secretion — making amylin replacement a mechanistically rational addition to GLP-1 agonist therapy in this population.
Phase 2 data from Novo Nordisk’s earlier CagriSema trials in type 2 diabetes showed HbA1c reductions of approximately 2.2% from baseline over 32 weeks, alongside weight loss of roughly 15–16% of body weight. This combination of HbA1c reduction and weight loss is particularly notable because the two outcomes tend to reinforce each other: weight loss improves insulin sensitivity and reduces hepatic fat, which further improves glycemic control in a cycle that monotherapy approaches struggle to sustain over time. The amylin component’s glucagon suppression contributes a distinct glycemic benefit that stacks on top of semaglutide’s GLP-1 mediated insulin secretagogue and glucagon-suppressive effects.
Full phase 3 data in the diabetes population is anticipated to provide definitive information about the long-term durability of these effects and the potential for this combination to reduce the need for additional antidiabetic medications.
Combination Therapy Advantages: Why Dual-Mechanism Beats Dose Escalation
A recurring question in the field of obesity pharmacotherapy is whether combining two moderate-dose agents from different mechanistic classes can outperform a high dose of a single agent. The CagriSema data provides meaningful evidence that the answer is yes, at least for the semaglutide-cagrilintide combination. This matters because high-dose escalation strategies often encounter a ceiling effect where marginal efficacy gains come at the cost of disproportionately increased side effects. In contrast, combining agents with distinct mechanisms allows each to be dosed in a range where efficacy is strong but tolerability is preserved.
In the case of CagriSema, the complementarity goes beyond receptor selectivity. The two agents engage satiety at different anatomical levels and with different temporal dynamics: cagrilintide provides rapid meal-onset satiety signals through the area postrema, while semaglutide modulates longer-term appetite regulation through hypothalamic circuits and delayed gastric emptying. They also address different aspects of post-meal glucose control — amylin receptor-mediated glucagon suppression and gastric emptying delay from cagrilintide, combined with GLP-1 receptor-mediated insulin potentiation and independent glucagon suppression from semaglutide. The result is a more complete pharmacological coverage of the pathophysiology of obesity and type 2 diabetes than either agent can provide alone.
Body Composition and Lean Mass Preservation
One of the legitimate concerns about any intensive weight loss intervention is the proportion of lean muscle mass lost alongside adipose tissue. Substantial muscle loss during rapid weight reduction can impair physical function, reduce resting metabolic rate, and create conditions for accelerated weight regain. While GLP-1 agonists are not particularly selective for fat loss over lean mass at the doses typically used, there is growing interest in whether combination approaches like CagriSema perform better in this respect.
Preliminary body composition analyses from phase 2 CagriSema trials have suggested a favorable fat-to-lean mass loss ratio, though the data at this stage are not conclusive and the mechanistic basis for any differential effect remains speculative. Amylin is known to interact with energy expenditure pathways through the brainstem and hypothalamus, and some preclinical data suggest amylin signaling may preferentially mobilize fat while attenuating the loss of metabolically active lean tissue. Whether this translates into a clinically meaningful preservation of lean mass at the doses used in CagriSema trials awaits dedicated body composition analysis from the larger phase 3 datasets.
Head-to-Head Considerations Against Tirzepatide
A natural question in the context of CagriSema’s impressive efficacy data is how it compares to tirzepatide (Mounjaro/Zepbound), the dual GIP/GLP-1 receptor agonist that has itself demonstrated substantial weight loss of approximately 20–22% in the SURMOUNT trial series. Direct head-to-head trials between CagriSema and tirzepatide have not yet been published, which makes any comparison premature. However, the mechanistic distinction is notable: tirzepatide combines GLP-1 and GIP receptor agonism, while CagriSema combines GLP-1 receptor agonism with amylin analog activity. These represent genuinely different mechanistic hypotheses about how best to amplify weight loss beyond GLP-1 monotherapy, and the field is watching with considerable interest to see which approach demonstrates greater long-term efficacy and tolerability in direct comparison.
Dosage and Administration
Cagrilintide Dose Escalation Schedule
In the REDEFINE clinical trials, cagrilintide is administered as a component of the CagriSema co-formulation and follows a dose escalation schedule that allows gradual accommodation to the compound. A representative phase 3 escalation schema involves starting at a low combined dose (typically 0.25 mg cagrilintide / 0.25 mg semaglutide) and increasing every four weeks through a series of escalation steps over approximately 16–20 weeks before reaching the maintenance dose of 2.4 mg cagrilintide / 2.4 mg semaglutide. This gradual escalation is primarily intended to minimize gastrointestinal side effects, particularly nausea and vomiting, which are more prevalent at higher doses and during the initial weeks of treatment.
As a research compound, cagrilintide is not currently approved for independent clinical use outside of clinical trials. Any consideration of its use should be approached with awareness of its investigational status and the absence of long-term safety data outside controlled trial conditions. For understanding how peptide dosing calculations work generally, the Peptide Calculator covers the fundamental dilution and dosing math.
Route of Administration
Cagrilintide, in both standalone and co-formulated form, is administered by subcutaneous injection. The once-weekly dosing schedule was specifically engineered through the fatty acid conjugation strategy described in the mechanism sections above. In the CagriSema co-formulation, both semaglutide and cagrilintide are delivered in a single injection, which Novo Nordisk has characterized as a key differentiating advantage over combination pill regimens or multi-injection protocols. Injection sites follow standard subcutaneous injection guidance — abdomen, thigh, or upper arm — with site rotation recommended to avoid lipohypertrophy at any single location.
Timing and Meal Considerations
Unlike GLP-1 receptor agonists that are generally administered without specific meal-time requirements, amylin analogs classically exert their primary glucoregulatory effects around mealtimes. However, because cagrilintide is a long-acting once-weekly agent with a stable plasma concentration profile, it does not require the peri-meal timing that was necessary with pramlintide (which had a half-life of approximately 48 minutes and was injected before each meal). Cagrilintide’s sustained pharmacokinetic profile means it maintains relatively consistent receptor engagement regardless of injection timing relative to meals, which is one of the practical advantages of the long-acting formulation approach.
Considerations for Research Context
Cagrilintide is currently an investigational compound with no approved standalone indication. All clinical data available at the time of this writing derives from Novo Nordisk-sponsored trials with specific inclusion and exclusion criteria, controlled titration protocols, and active medical monitoring. Researchers and clinicians following this compound should consult the published REDEFINE trial protocols for the specific dose titration schedules and monitoring parameters used in those studies. The AI Coach can help contextualize published dosing data within broader peptide pharmacology frameworks, though it should not be used as a substitute for clinical trial protocol guidance.
Safety and Side Effects
Gastrointestinal Adverse Events
The most commonly reported adverse events in CagriSema trials are gastrointestinal in nature: nausea, vomiting, diarrhea, and constipation. These are broadly consistent with the established side effect profile of semaglutide and other GLP-1 receptor agonists, though the amylin component may contribute additional gastric motility effects given cagrilintide’s independent gastric emptying-slowing mechanism. In the REDEFINE 1 trial, nausea affected a meaningfully higher proportion of CagriSema participants than semaglutide-alone participants, though the majority of cases were reported as mild to moderate and most resolved over the first weeks of treatment as tolerance developed. The dose escalation schedule is specifically designed to minimize the severity and duration of these effects by allowing physiological accommodation at each dose level before advancing.
Injection Site Reactions and Long-term Tolerability
Injection site reactions — including erythema, pruritis, and nodule formation — have been reported in a subset of CagriSema trial participants and may be somewhat more frequent with the co-formulation than with semaglutide alone, potentially due to the volume of the combined injection or to immunological responses to the amylin component. Proper injection technique, site rotation across the abdomen, thigh, and upper arm, and attention to subcutaneous (rather than intradermal) delivery are standard measures to minimize injection site issues. Longer-term tolerability data from the ongoing phase 3 trials will provide a more complete picture of whether any adverse events with delayed onset emerge with sustained once-weekly dosing over 68 weeks or longer.
Hypoglycemia Risk and Contraindications
Amylin analogs in general carry a risk of hypoglycemia when used in combination with insulin, and pramlintide carries an FDA black box warning for this reason. In the CagriSema context, neither semaglutide nor cagrilintide independently drives insulin secretion in a glucose-independent manner — GLP-1 receptor agonists are glucose-dependent in their insulin-stimulating effect — which means the hypoglycemia risk in the absence of concomitant insulin therapy is substantially lower than with pramlintide-insulin combinations. Nevertheless, individuals on insulin therapy who also use CagriSema require careful dose adjustment of their insulin to account for the improved glycemic control produced by the combination. Other standard GLP-1 agonist precautions apply: CagriSema should be used cautiously in people with a personal or family history of medullary thyroid carcinoma or MEN2, and there are standard contraindications related to pancreatitis history and severe gastrointestinal disease that apply to both components of the combination.
Frequently Asked Questions
Both are amylin analogs, but they differ substantially in pharmacokinetics and therefore in practical utility. Pramlintide (Symlin) has a half-life of approximately 48 minutes and requires injection before each major meal, making it cumbersome to use and limiting patient adherence. Cagrilintide has been engineered with a fatty acid chain that enables albumin binding, extending its half-life to approximately one week and allowing convenient once-weekly dosing. This pharmacokinetic improvement is what makes cagrilintide a viable candidate for combination with semaglutide in a single weekly co-injection.
As of early 2026, CagriSema had not received FDA approval. It was in phase 3 clinical trials across the REDEFINE program, with Novo Nordisk pursuing regulatory submissions based on accumulating efficacy and safety data. Approval timelines depend on the completion of the full REDEFINE trial program and regulatory review, processes that typically take several years from the completion of pivotal trials. Cagrilintide as a standalone compound has also not received regulatory approval for any indication.
In the REDEFINE 1 phase 3 trial, CagriSema produced approximately 22.7% mean body weight loss compared to approximately 16.1% with semaglutide 2.4 mg alone — a difference of roughly 6–7 percentage points. While absolute percentages will vary across individual trials based on population characteristics and trial duration, the consistent finding across phase 2 and phase 3 data is that CagriSema meaningfully outperforms semaglutide monotherapy at matched semaglutide doses. This delta represents a substantial clinical difference, as each additional percentage point of body weight lost is associated with meaningful improvements in metabolic risk markers, physical function, and quality of life.
No. Cagrilintide acts through amylin receptors (AMY1, AMY2, AMY3), which are heterodimeric complexes formed by the calcitonin receptor and receptor activity-modifying proteins. These are completely distinct from GLP-1 receptors, which are single-subunit G protein-coupled receptors of the class B GPCR family. The mechanistic distinction is precisely what makes the combination therapeutically interesting — engaging two separate receptor systems means the combined therapy is not simply a higher dose of one mechanism, but rather a broader engagement of the physiological pathways that regulate appetite, gastric emptying, and glucose homeostasis.
Caution is required when using any amylin analog alongside insulin. Pramlintide carries a black box warning for severe hypoglycemia when combined with insulin, and while cagrilintide’s glucose-dependent mechanism reduces the standalone hypoglycemia risk, the improved glycemic control produced by the combination can require significant downward adjustment of insulin doses. Anyone on insulin therapy who is participating in a CagriSema trial or considering amylin analog use should do so under close medical supervision with regular glucose monitoring and proactive insulin dose adjustment.
REDEFINE is Novo Nordisk’s phase 3 clinical trial program evaluating CagriSema across multiple populations. REDEFINE 1 enrolled adults with obesity or overweight with comorbidities; REDEFINE 2 enrolled adults with type 2 diabetes. Additional arms of the program evaluate CagriSema in populations with specific comorbidities including cardiovascular disease. Together, the REDEFINE trials represent the clinical evidence base that Novo Nordisk intends to use to support regulatory approval applications for CagriSema as a fixed-dose co-formulation.
This is an astute question. Native amylin acts acutely — rising with meal initiation and acting as a real-time meal-termination signal. Cagrilintide, with its one-week half-life, maintains a relatively constant steady-state plasma concentration rather than pulsing with meals. The mechanism by which this sustained amylin receptor occupancy translates into weight loss is not fully characterized, but it likely involves tonic suppression of appetite set-points through the area postrema and hypothalamic circuits rather than acute meal-to-meal signaling. The body’s weight regulatory system responds to sustained amylin receptor engagement by resetting appetite and food reward signals downward, similar in principle to how sustained GLP-1 receptor activation by semaglutide produces weight loss through tonic rather than pulsatile signaling.
The Peptide Database contains entries on semaglutide, tirzepatide, and other metabolic peptides with detailed mechanistic and clinical summaries. The AI Coach can help contextualize how different metabolic peptides compare and what the published research shows about combination approaches. For anyone looking to understand the dosing arithmetic behind any of these compounds, the Peptide Calculator provides reconstitution and dosing calculation tools.
References
- Rosenstock J, et al. “CagriSema versus semaglutide in adults with type 2 diabetes: a randomized phase 2 trial.” The Lancet. 2023. PubMed
- Enebo LB, et al. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2·4 mg for weight management in adults with overweight and obesity.” The Lancet. 2021;397(10286):1736–1748. PubMed
- Christopoulos G, et al. “Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product.” Molecular Pharmacology. 1999;56(1):235–242. PubMed
- Lutz TA. “The role of amylin in the control of energy homeostasis.” American Journal of Physiology – Regulatory, Integrative and Comparative Physiology. 2010;298(6):R1475–R1484. PubMed
- Frias JP, et al. “Efficacy and safety of tirzepatide, a dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes.” New England Journal of Medicine. 2021;385(6):503–515. PubMed
- Aronne LJ, et al. “Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity.” JAMA. 2024;331(1):38–48. PubMed
- Hay DL, et al. “Amylin: Pharmacology, Physiology, and Clinical Potential.” Pharmacological Reviews. 2015;67(3):564–600. PubMed
- Novo Nordisk. “REDEFINE 1 Phase 3 Trial Results.” ClinicalTrials.gov Identifier: NCT05567796. PubMed